The Department of Pharmaceutical Services under Antigua and Barbuda’s Ministry of Health, Wellness, the Environment and Civil Service Affairs has issued a public notification alerting consumers, healthcare providers, pharmacies, drug wholesalers, distributors and other industry stakeholders to a coordinated recall of three separate lines of pharmaceutical products that have entered distribution channels across the island nation.
The first recall centers on a specific lot of Novartis’ Diovan 160 mg tablets, a widely prescribed valsartan-based medication classified as an angiotensin II receptor blocker used to manage high blood pressure and heart failure. The voluntary recall was first announced by the U.S. Food and Drug Administration (FDA) on August 4, 2026, after quality testing revealed the product failed to meet required dissolution specifications. This means the tablet does not break down at the expected rate in the body, preventing proper absorption of the active ingredient. The FDA has categorized this recall as Class II, a designation indicating that while temporary or reversible adverse health effects are a possible outcome of use, the risk of serious, life-threatening harm is extremely low. The only affected batch carries lot number AV5913C with an expiration date of June 20, 2027.
Regulators have issued clear guidance for patients holding this specific Diovan lot: the recalled medication should not be thrown away with regular household trash. Instead, any unused portions must be returned to the original dispensing pharmacy or the wholesale distributor that supplied the product. Crucially, patients are warned not to discontinue use of their blood pressure or heart failure medication without first consulting a prescribing doctor or pharmacist, as abrupt stopping of these treatments can create significant, immediate health risks.
A second recall, classified as Category II Level 2, covers specific batches of 10 mg and 20 mg Atorstan (atorvastatin) tablets manufactured by Cyprus-based drug producer Remedica. Atorvastatin is a commonly prescribed statin used to lower LDL cholesterol and reduce cardiovascular disease risk. All affected batches remain within their approved shelf life and have been distributed across Antigua and Barbuda. The recall was launched after ongoing stability testing at the manufacturing facility returned out-of-specification results for the product. While current risk assessments have found no indication of severe danger to patient safety, regulators ordered the recall as a precautionary measure to uphold regulatory compliance and protect public health.
The affected Atorstan batches are: 129702 (10 mg, exp. April 17, 2028), 125293 (10 mg, exp. July 23, 2027), 123164 (20 mg, exp. April 3, 2027), 128946 (20 mg, exp. December 18, 2027), and 129730 (20 mg, exp. April 17, 2028). Patients holding any of these batches are required to return the product to the point of purchase by the September 4, 2026 deadline. As with Diovan, patients are advised not to stop taking atorvastatin without consulting a healthcare provider, who can supply an alternative product or adjust the treatment plan if needed.
The third recall involves four lots of 5 mg Cetirizine Hydrochloride USP 100-tablet bottles, a widely used over-the-counter and prescription antihistamine for treating allergy symptoms. The voluntary recall was initiated by manufacturer Unique Pharmaceutical Laboratories, a division of India-based J.B. Chemicals & Pharmaceuticals Ltd., which distributes the product in the region through Rising Pharma Holdings Inc. The safety issue was first flagged after a consumer complaint reported unexplained red dots and discoloration on tablet surfaces. Further investigation found potential cross-contamination with ranitidine, a histamine-2 blocker previously used to treat acid reflux.
Manufacturers warn that for patients with a confirmed hypersensitivity to ranitidine, exposure to contaminated cetirizine could trigger severe allergic reactions, including life-threatening anaphylaxis. As of the recall announcement, the manufacturer has not received any reports of adverse events linked to the affected lots. The affected batches, all with an October 2028 expiration date, carry lot codes GY825029, GY825030, GY825031, and GY825032. Consumers are instructed to immediately stop using any cetirizine from these lots, return the product to the point of purchase, and contact a healthcare provider if they have experienced any unexplained health issues after using the product. Medical inquiries about the recall can be directed to Rising Pharma Holdings Inc. during regular business hours (8 a.m. to 5 p.m. EST, Monday through Friday).
In closing, the Department of Pharmaceutical Services stressed that while the public does not need to panic, it is critical that all stakeholders take the recall notices seriously. Consumers are encouraged to carefully check the lot numbers, product names, and dosage strengths of any medications they hold at home, and return confirmed affected products to the appropriate dispensing or distribution point immediately. The department has also ordered all pharmacies, wholesalers, distributors, and healthcare providers to conduct immediate inventory checks to pull all recalled products from circulation, preventing further distribution to patients.
The Ministry of Health reaffirmed its ongoing commitment to protecting the health and well-being of all residents of Antigua and Barbuda, noting that it will continue to monitor the unfolding recall situation and update the public with any new information as it becomes available.
